Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Go back to Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform| (NASDAQ: PSNL) | Delayed: 17.20 +0.37 (2.20%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.83 | 52 Week High | $ | |||
| Open | $16.67 | 52 Week Low | $ | |||
| Day High | $17.23 | P/E | N/A | |||
| Day Low | $16.52 | EPS | $ | |||
| Volume | 2,522,867 | |||||
| StemCells, Inc. (NASDAQ: TEM) | Delayed: 64.62 -0.04 (0.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.66 | 52 Week High | $0.45 | |||
| Open | $64.76 | 52 Week Low | $0.37 | |||
| Day High | $66.30 | P/E | N/A | |||
| Day Low | $63.11 | EPS | $-0.31 | |||
| Volume | 4,574,993 | |||||

